| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | RNA helicase activity | 4.49e-05 | 78 | 18 | 3 | GO:0003724 | |
| GeneOntologyMolecularFunction | ATP-dependent activity, acting on RNA | 4.84e-05 | 80 | 18 | 3 | GO:0008186 | |
| GeneOntologyMolecularFunction | peroxisome proliferator activated receptor binding | 1.60e-04 | 21 | 18 | 2 | GO:0042975 | |
| GeneOntologyMolecularFunction | helicase activity | 3.63e-04 | 158 | 18 | 3 | GO:0004386 | |
| GeneOntologyMolecularFunction | nuclear estrogen receptor binding | 1.03e-03 | 53 | 18 | 2 | GO:0030331 | |
| GeneOntologyMolecularFunction | ATP-dependent activity | 1.92e-03 | 614 | 18 | 4 | GO:0140657 | |
| GeneOntologyMolecularFunction | catalytic activity, acting on RNA | 5.84e-03 | 417 | 18 | 3 | GO:0140098 | |
| GeneOntologyMolecularFunction | ATP hydrolysis activity | 6.82e-03 | 441 | 18 | 3 | GO:0016887 | |
| GeneOntologyBiologicalProcess | rRNA processing | 3.20e-05 | 230 | 17 | 4 | GO:0006364 | |
| GeneOntologyBiologicalProcess | rRNA metabolic process | 6.42e-05 | 275 | 17 | 4 | GO:0016072 | |
| GeneOntologyBiologicalProcess | RNA processing | 1.08e-04 | 1500 | 17 | 7 | GO:0006396 | |
| GeneOntologyBiologicalProcess | ribosome biogenesis | 1.39e-04 | 336 | 17 | 4 | GO:0042254 | |
| GeneOntologyBiologicalProcess | maturation of SSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA) | 4.19e-04 | 37 | 17 | 2 | GO:0000462 | |
| GeneOntologyBiologicalProcess | ribonucleoprotein complex biogenesis | 7.06e-04 | 515 | 17 | 4 | GO:0022613 | |
| GeneOntologyBiologicalProcess | maturation of SSU-rRNA | 9.25e-04 | 55 | 17 | 2 | GO:0030490 | |
| Domain | DEAD/DEAH_box_helicase_dom | 4.48e-05 | 73 | 18 | 3 | IPR011545 | |
| Domain | DEAD | 4.48e-05 | 73 | 18 | 3 | PF00270 | |
| Domain | Helicase_C | 1.40e-04 | 107 | 18 | 3 | PF00271 | |
| Domain | HELICc | 1.40e-04 | 107 | 18 | 3 | SM00490 | |
| Domain | Helicase_C | 1.44e-04 | 108 | 18 | 3 | IPR001650 | |
| Domain | HELICASE_CTER | 1.48e-04 | 109 | 18 | 3 | PS51194 | |
| Domain | HELICASE_ATP_BIND_1 | 1.48e-04 | 109 | 18 | 3 | PS51192 | |
| Domain | DEXDc | 1.48e-04 | 109 | 18 | 3 | SM00487 | |
| Domain | Helicase_ATP-bd | 1.52e-04 | 110 | 18 | 3 | IPR014001 | |
| Domain | DEAD_ATP_HELICASE | 4.01e-04 | 31 | 18 | 2 | PS00039 | |
| Domain | RNA-helicase_DEAD-box_CS | 4.55e-04 | 33 | 18 | 2 | IPR000629 | |
| Domain | RNA_helicase_DEAD_Q_motif | 5.73e-04 | 37 | 18 | 2 | IPR014014 | |
| Domain | Q_MOTIF | 5.73e-04 | 37 | 18 | 2 | PS51195 | |
| Domain | P-loop_NTPase | 9.96e-04 | 848 | 18 | 5 | IPR027417 | |
| Domain | - | 4.94e-03 | 746 | 18 | 4 | 3.40.50.300 | |
| Pubmed | BAP1 regulation of the key adaptor protein NCoR1 is critical for γ-globin gene repression. | 1.30e-07 | 1318 | 18 | 8 | 30463901 | |
| Pubmed | Interactome Analysis of the Nucleocapsid Protein of SARS-CoV-2 Virus. | 1.22e-06 | 159 | 18 | 4 | 34578187 | |
| Pubmed | 1.22e-06 | 159 | 18 | 4 | 22751105 | ||
| Pubmed | 1.52e-06 | 4 | 18 | 2 | 31256877 | ||
| Pubmed | 1.61e-05 | 653 | 18 | 5 | 22586326 | ||
| Pubmed | 1.86e-05 | 1168 | 18 | 6 | 19946888 | ||
| Pubmed | PTPN14 regulates Roquin2 stability by tyrosine dephosphorylation. | 1.93e-05 | 678 | 18 | 5 | 30209976 | |
| Pubmed | Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia. | 2.05e-05 | 104 | 18 | 3 | 26167872 | |
| Pubmed | ZBTB2 protein is a new partner of the Nucleosome Remodeling and Deacetylase (NuRD) complex. | 2.19e-05 | 330 | 18 | 4 | 33301849 | |
| Pubmed | 2.76e-05 | 731 | 18 | 5 | 29298432 | ||
| Pubmed | The E3 ubiquitin ligase HECTD1 contributes to cell proliferation through an effect on mitosis. | 3.31e-05 | 759 | 18 | 5 | 35915203 | |
| Pubmed | The cell proliferation antigen Ki-67 organises heterochromatin. | 5.11e-05 | 410 | 18 | 4 | 26949251 | |
| Pubmed | 5.57e-05 | 847 | 18 | 5 | 35850772 | ||
| Pubmed | Gain of Additional BIRC3 Protein Functions through 3'-UTR-Mediated Protein Complex Formation. | 5.68e-05 | 1425 | 18 | 6 | 30948266 | |
| Pubmed | 5.77e-05 | 1429 | 18 | 6 | 35140242 | ||
| Pubmed | 7.39e-05 | 451 | 18 | 4 | 30033366 | ||
| Pubmed | TBK1 phosphorylation activates LIR-dependent degradation of the inflammation repressor TNIP1. | 9.54e-05 | 949 | 18 | 5 | 36574265 | |
| Pubmed | 9.63e-05 | 483 | 18 | 4 | 36912080 | ||
| Pubmed | 1.06e-04 | 971 | 18 | 5 | 33306668 | ||
| Pubmed | MYC multimers shield stalled replication forks from RNA polymerase. | 1.16e-04 | 989 | 18 | 5 | 36424410 | |
| Pubmed | 1.30e-04 | 1014 | 18 | 5 | 32416067 | ||
| Pubmed | MECP2 directly interacts with RNA polymerase II to modulate transcription in human neurons. | 1.76e-04 | 1082 | 18 | 5 | 38697112 | |
| Pubmed | The deubiquitinase USP7 stabilizes Maf proteins to promote myeloma cell survival. | 1.90e-04 | 220 | 18 | 3 | 31822558 | |
| Pubmed | CHD3 and CHD4 form distinct NuRD complexes with different yet overlapping functionality. | 2.29e-04 | 605 | 18 | 4 | 28977666 | |
| Pubmed | The in vivo Interaction Landscape of Histones H3.1 and H3.3. | 2.33e-04 | 608 | 18 | 4 | 36089195 | |
| Pubmed | 2.36e-04 | 44 | 18 | 2 | 26471122 | ||
| Pubmed | ALS/FTD-causing mutation in cyclin F causes the dysregulation of SFPQ. | 2.57e-04 | 624 | 18 | 4 | 33729478 | |
| Pubmed | FOXA1 Directs H3K4 Monomethylation at Enhancers via Recruitment of the Methyltransferase MLL3. | 2.70e-04 | 248 | 18 | 3 | 27926873 | |
| Pubmed | 3.06e-04 | 653 | 18 | 4 | 33742100 | ||
| Pubmed | A screen for downstream effectors of Neurogenin2 in the embryonic neocortex. | 3.30e-04 | 52 | 18 | 2 | 15328020 | |
| Pubmed | Targeting USP10 induces degradation of oncogenic ANLN in esophageal squamous cell carcinoma. | 3.54e-04 | 1257 | 18 | 5 | 36526897 | |
| Pubmed | MBD5 and MBD6 stabilize the BAP1 complex and promote BAP1-dependent cancer. | 4.14e-04 | 287 | 18 | 3 | 36180891 | |
| Pubmed | 4.26e-04 | 713 | 18 | 4 | 29802200 | ||
| Pubmed | 4.49e-04 | 723 | 18 | 4 | 34133714 | ||
| Pubmed | Proteomic profiling of VCP substrates links VCP to K6-linked ubiquitylation and c-Myc function. | 4.96e-04 | 1353 | 18 | 5 | 29467282 | |
| Interaction | H3C1 interactions | 2.32e-08 | 901 | 18 | 9 | int:H3C1 | |
| Interaction | TLX2 interactions | 1.29e-07 | 142 | 18 | 5 | int:TLX2 | |
| Interaction | SCARNA22 interactions | 3.21e-06 | 118 | 18 | 4 | int:SCARNA22 | |
| Interaction | NEIL1 interactions | 3.44e-06 | 276 | 18 | 5 | int:NEIL1 | |
| Interaction | NR2C2 interactions | 1.26e-05 | 1403 | 18 | 8 | int:NR2C2 | |
| Interaction | SNRNP40 interactions | 1.31e-05 | 637 | 18 | 6 | int:SNRNP40 | |
| Interaction | ZNF346 interactions | 1.56e-05 | 377 | 18 | 5 | int:ZNF346 | |
| Interaction | CENPA interactions | 1.56e-05 | 377 | 18 | 5 | int:CENPA | |
| Interaction | MEN1 interactions | 1.72e-05 | 1029 | 18 | 7 | int:MEN1 | |
| Interaction | APOBEC3C interactions | 1.98e-05 | 187 | 18 | 4 | int:APOBEC3C | |
| Interaction | SURF6 interactions | 2.81e-05 | 426 | 18 | 5 | int:SURF6 | |
| Interaction | SIRT7 interactions | 3.15e-05 | 744 | 18 | 6 | int:SIRT7 | |
| Interaction | CDKL2 interactions | 3.29e-05 | 71 | 18 | 3 | int:CDKL2 | |
| Interaction | RBM19 interactions | 3.82e-05 | 221 | 18 | 4 | int:RBM19 | |
| Interaction | SRSF5 interactions | 4.69e-05 | 474 | 18 | 5 | int:SRSF5 | |
| Interaction | ZNF394 interactions | 5.84e-05 | 13 | 18 | 2 | int:ZNF394 | |
| Interaction | FGFBP1 interactions | 6.87e-05 | 257 | 18 | 4 | int:FGFBP1 | |
| Interaction | MBD6 interactions | 6.92e-05 | 91 | 18 | 3 | int:MBD6 | |
| Interaction | MECP2 interactions | 7.26e-05 | 1287 | 18 | 7 | int:MECP2 | |
| Interaction | RPS24 interactions | 7.89e-05 | 529 | 18 | 5 | int:RPS24 | |
| Interaction | AURKAIP1 interactions | 1.01e-04 | 284 | 18 | 4 | int:AURKAIP1 | |
| Interaction | YBX2 interactions | 1.08e-04 | 289 | 18 | 4 | int:YBX2 | |
| Interaction | RPS10 interactions | 1.09e-04 | 567 | 18 | 5 | int:RPS10 | |
| Interaction | NOP56 interactions | 1.12e-04 | 570 | 18 | 5 | int:NOP56 | |
| Interaction | CDC14A interactions | 1.25e-04 | 111 | 18 | 3 | int:CDC14A | |
| Interaction | TEK interactions | 1.54e-04 | 119 | 18 | 3 | int:TEK | |
| Interaction | FBL interactions | 1.92e-04 | 639 | 18 | 5 | int:FBL | |
| Interaction | H1-4 interactions | 2.17e-04 | 656 | 18 | 5 | int:H1-4 | |
| Interaction | MAGEB2 interactions | 2.23e-04 | 349 | 18 | 4 | int:MAGEB2 | |
| Interaction | RC3H2 interactions | 2.34e-04 | 667 | 18 | 5 | int:RC3H2 | |
| Interaction | RC3H1 interactions | 2.51e-04 | 677 | 18 | 5 | int:RC3H1 | |
| Interaction | EIF2AK2 interactions | 2.54e-04 | 361 | 18 | 4 | int:EIF2AK2 | |
| Interaction | EPHB4 interactions | 2.81e-04 | 146 | 18 | 3 | int:EPHB4 | |
| Interaction | SRPK2 interactions | 3.27e-04 | 717 | 18 | 5 | int:SRPK2 | |
| Interaction | DDX21 interactions | 3.29e-04 | 718 | 18 | 5 | int:DDX21 | |
| Interaction | FZR1 interactions | 3.87e-04 | 1172 | 18 | 6 | int:FZR1 | |
| Interaction | NPM1 interactions | 4.41e-04 | 1201 | 18 | 6 | int:NPM1 | |
| Interaction | LIN28A interactions | 4.55e-04 | 421 | 18 | 4 | int:LIN28A | |
| Interaction | NIFK interactions | 4.98e-04 | 431 | 18 | 4 | int:NIFK | |
| Interaction | ZNF330 interactions | 5.66e-04 | 446 | 18 | 4 | int:ZNF330 | |
| Interaction | ZBTB2 interactions | 5.85e-04 | 450 | 18 | 4 | int:ZBTB2 | |
| Interaction | MNDA interactions | 5.88e-04 | 188 | 18 | 3 | int:MNDA | |
| Interaction | SRPK3 interactions | 6.06e-04 | 190 | 18 | 3 | int:SRPK3 | |
| Interaction | ZC3H10 interactions | 7.04e-04 | 200 | 18 | 3 | int:ZC3H10 | |
| Interaction | PPP2CA interactions | 7.69e-04 | 484 | 18 | 4 | int:PPP2CA | |
| Interaction | BIRC3 interactions | 7.73e-04 | 1334 | 18 | 6 | int:BIRC3 | |
| Interaction | POLR1G interactions | 7.99e-04 | 489 | 18 | 4 | int:POLR1G | |
| Interaction | ZC3H18 interactions | 8.23e-04 | 877 | 18 | 5 | int:ZC3H18 | |
| Interaction | MYO3B interactions | 9.00e-04 | 50 | 18 | 2 | int:MYO3B | |
| Interaction | CLK1 interactions | 9.16e-04 | 219 | 18 | 3 | int:CLK1 | |
| Interaction | MAPRE1 interactions | 9.63e-04 | 514 | 18 | 4 | int:MAPRE1 | |
| Interaction | PURG interactions | 9.65e-04 | 223 | 18 | 3 | int:PURG | |
| Interaction | OASL interactions | 9.65e-04 | 223 | 18 | 3 | int:OASL | |
| Interaction | RPS9 interactions | 9.70e-04 | 515 | 18 | 4 | int:RPS9 | |
| Interaction | EP300 interactions | 1.00e-03 | 1401 | 18 | 6 | int:EP300 | |
| Interaction | ZNF668 interactions | 1.00e-03 | 226 | 18 | 3 | int:ZNF668 | |
| Interaction | MAST1 interactions | 1.03e-03 | 228 | 18 | 3 | int:MAST1 | |
| Interaction | H1-6 interactions | 1.04e-03 | 229 | 18 | 3 | int:H1-6 | |
| Interaction | RPS14 interactions | 1.07e-03 | 529 | 18 | 4 | int:RPS14 | |
| Interaction | EED interactions | 1.18e-03 | 1445 | 18 | 6 | int:EED | |
| Interaction | MAFB interactions | 1.28e-03 | 246 | 18 | 3 | int:MAFB | |
| Interaction | PRR3 interactions | 1.28e-03 | 246 | 18 | 3 | int:PRR3 | |
| Interaction | SYK interactions | 1.36e-03 | 251 | 18 | 3 | int:SYK | |
| Interaction | HECTD1 interactions | 1.38e-03 | 984 | 18 | 5 | int:HECTD1 | |
| Interaction | SNRNP70 interactions | 1.38e-03 | 984 | 18 | 5 | int:SNRNP70 | |
| Interaction | RBBP4 interactions | 1.44e-03 | 573 | 18 | 4 | int:RBBP4 | |
| Interaction | PSKH1 interactions | 1.52e-03 | 65 | 18 | 2 | int:PSKH1 | |
| Interaction | NPM3 interactions | 1.53e-03 | 262 | 18 | 3 | int:NPM3 | |
| Interaction | RBM4B interactions | 1.53e-03 | 262 | 18 | 3 | int:RBM4B | |
| Interaction | FGF3 interactions | 1.56e-03 | 66 | 18 | 2 | int:FGF3 | |
| Interaction | USP36 interactions | 1.70e-03 | 599 | 18 | 4 | int:USP36 | |
| Interaction | REST interactions | 1.74e-03 | 274 | 18 | 3 | int:REST | |
| Interaction | CBX6 interactions | 1.91e-03 | 283 | 18 | 3 | int:CBX6 | |
| Interaction | NUP43 interactions | 1.98e-03 | 625 | 18 | 4 | int:NUP43 | |
| Interaction | SIRT6 interactions | 2.02e-03 | 628 | 18 | 4 | int:SIRT6 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr18q12 | 7.59e-04 | 104 | 18 | 2 | chr18q12 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr12q24 | 1.13e-02 | 415 | 18 | 2 | chr12q24 | |
| GeneFamily | DEAD-box helicases | 1.88e-04 | 42 | 9 | 2 | 499 | |
| ToppCell | LPS-antiTNF-Stromal_mesenchymal-Fibroblasts-Monocytes-Macrophages|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.91e-05 | 151 | 18 | 3 | f13a117ae26ae525da4f3e837d8f204d00dc6ee3 | |
| ToppCell | severe-HSPC|severe / disease stage, cell group and cell class | 3.80e-05 | 165 | 18 | 3 | acd837d88ad3786c263f74651a6c0e02fa2fa2c5 | |
| ToppCell | ICU-NoSEP-Lymphocyte-T_NK-NK_CD56bright|ICU-NoSEP / Disease, Lineage and Cell Type | 3.93e-05 | 167 | 18 | 3 | f4f188a8efca8cdd0ecfb857fe4538c10847eadd | |
| ToppCell | TCGA-Uvea-Primary_Tumor-Uveal_Melanoma-Spindle_Cell-1|TCGA-Uvea / Sample_Type by Project: Shred V9 | 4.00e-05 | 168 | 18 | 3 | b427746929bb40e3d1b5f1c40d302b792d6b32a5 | |
| ToppCell | severe-HSPC|World / disease stage, cell group and cell class | 4.08e-05 | 169 | 18 | 3 | b0421b73bfdc92f7a2762b4b670b9eae124aa702 | |
| ToppCell | Adult-Mesenchymal-matrix_fibroblast_1_cell-D175|Adult / Lineage, Cell type, age group and donor | 5.51e-05 | 187 | 18 | 3 | e15d2967aac248da3517bc2c7d1beaa1d5a0aa7f | |
| ToppCell | H1299-infected-SARSCoV2|infected / Cell line, Condition and Strain | 6.43e-05 | 197 | 18 | 3 | 0fa3e4cf93e77d78b1f97b906c5b13ca741ae17e | |
| ToppCell | Sepsis-ICU-NoSEP-Lymphocyte-T/NK-NK_CD56bright|ICU-NoSEP / Disease, condition lineage and cell class | 6.72e-05 | 200 | 18 | 3 | c2df917900872453ea17a39928e39d071a6d3339 | |
| Drug | Azlocillin sodium salt [37091-65-9]; Down 200; 8.2uM; HL60; HT_HG-U133A | 1.45e-05 | 195 | 18 | 4 | 2727_DN | |
| Drug | baccatin III | 3.87e-04 | 37 | 18 | 2 | CID000065366 | |
| Drug | Fluticasone propionate [80474-14-2]; Down 200; 8uM; HL60; HT_HG-U133A | 4.19e-04 | 189 | 18 | 3 | 2928_DN | |
| Drug | 5230742; Up 200; 17uM; MCF7; HT_HG-U133A_EA | 4.26e-04 | 190 | 18 | 3 | 970_UP | |
| Drug | olmesartan medoxomil | 4.30e-04 | 39 | 18 | 2 | CID000130881 | |
| Drug | retinoic acid; Down 200; 1uM; MCF7; HT_HG-U133A_EA | 4.32e-04 | 191 | 18 | 3 | 991_DN | |
| Drug | Heptaminol hydrochloride [543-15-7]; Up 200; 22uM; MCF7; HT_HG-U133A | 4.46e-04 | 193 | 18 | 3 | 1703_UP | |
| Drug | Chlorprothixene hydrochloride [6469-93-8]; Down 200; 11.4uM; MCF7; HT_HG-U133A | 4.46e-04 | 193 | 18 | 3 | 5291_DN | |
| Drug | Methylhydantoin-5-(D) [55147-68-7]; Down 200; 35uM; MCF7; HT_HG-U133A | 4.46e-04 | 193 | 18 | 3 | 4113_DN | |
| Drug | Thiamphenicol [15318-45-3]; Down 200; 11.2uM; MCF7; HT_HG-U133A | 4.46e-04 | 193 | 18 | 3 | 7033_DN | |
| Drug | 17-DMAG; Down 200; 0.1uM; MCF7; HT_HG-U133A | 4.52e-04 | 194 | 18 | 3 | 6933_DN | |
| Drug | GSK-3 Inhibitor IX; Up 200; 0.5uM; MCF7; HT_HG-U133A | 4.52e-04 | 194 | 18 | 3 | 7044_UP | |
| Drug | Prilocaine hydrochloride [1786-81-8]; Down 200; 15.6uM; PC3; HT_HG-U133A | 4.52e-04 | 194 | 18 | 3 | 4284_DN | |
| Drug | DO 897/99; Down 200; 8.2uM; HL60; HG-U133A | 4.52e-04 | 194 | 18 | 3 | 1728_DN | |
| Drug | Norfloxacin [70458-96-7]; Down 200; 12.6uM; PC3; HT_HG-U133A | 4.52e-04 | 194 | 18 | 3 | 7283_DN | |
| Drug | 2-propylpentanoic acid; Up 200; 50uM; MCF7; HT_HG-U133A_EA | 4.52e-04 | 194 | 18 | 3 | 1060_UP | |
| Drug | Fluspirilen [1841-19-6]; Down 200; 8.4uM; PC3; HT_HG-U133A | 4.59e-04 | 195 | 18 | 3 | 6662_DN | |
| Drug | Aceclofenac [89796-99-6]; Down 200; 11.2uM; PC3; HT_HG-U133A | 4.66e-04 | 196 | 18 | 3 | 7269_DN | |
| Drug | Loxapine succinate [27833-64-3]; Down 200; 9uM; MCF7; HT_HG-U133A | 4.66e-04 | 196 | 18 | 3 | 5293_DN | |
| Drug | Esculin Hydrate [531-75-9]; Down 200; 11.8uM; MCF7; HT_HG-U133A | 4.66e-04 | 196 | 18 | 3 | 5411_DN | |
| Drug | Fenoprofen calcium salt dihydrate [53746-45-5]; Down 200; 7.2uM; HL60; HT_HG-U133A | 4.66e-04 | 196 | 18 | 3 | 2553_DN | |
| Drug | Riboflavine [83-88-5]; Up 200; 10.6uM; HL60; HG-U133A | 4.73e-04 | 197 | 18 | 3 | 1767_UP | |
| Drug | Cotinine (-) [486-56-6]; Down 200; 22.6uM; HL60; HG-U133A | 4.73e-04 | 197 | 18 | 3 | 2011_DN | |
| Drug | Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A | 4.73e-04 | 197 | 18 | 3 | 6222_DN | |
| Drug | Carbamazepine [298-46-4]; Down 200; 17uM; MCF7; HT_HG-U133A | 4.73e-04 | 197 | 18 | 3 | 5518_DN | |
| Drug | Fluoxetine hydrochloride [59333-67-4]; Down 200; 11.6uM; MCF7; HT_HG-U133A | 4.73e-04 | 197 | 18 | 3 | 5356_DN | |
| Drug | THIP Hydrochloride; Up 200; 22.6uM; PC3; HT_HG-U133A | 4.73e-04 | 197 | 18 | 3 | 7266_UP | |
| Drug | Iproniazide phosphate [305-33-9]; Down 200; 14.4uM; PC3; HT_HG-U133A | 4.73e-04 | 197 | 18 | 3 | 6359_DN | |
| Drug | 2-propylpentanoic acid; Down 200; 50uM; MCF7; HT_HG-U133A | 4.73e-04 | 197 | 18 | 3 | 6941_DN | |
| Drug | Cytisine (-) [485-35-8]; Down 200; 21uM; MCF7; HT_HG-U133A | 4.73e-04 | 197 | 18 | 3 | 6217_DN | |
| Drug | Lidocaone hydrochloride [73-78-9]; Up 200; 14.8uM; PC3; HG-U133A | 4.80e-04 | 198 | 18 | 3 | 1917_UP | |
| Drug | Ganciclovir [82410-32-0]; Down 200; 15.6uM; MCF7; HT_HG-U133A | 4.80e-04 | 198 | 18 | 3 | 5389_DN | |
| Drug | Estradiol-17 beta [50-28-2]; Down 200; 14.6uM; HL60; HT_HG-U133A | 4.80e-04 | 198 | 18 | 3 | 1299_DN | |
| Drug | Metanephrine hydrochloride DL [881-95-8]; Down 200; 17.2uM; MCF7; HT_HG-U133A | 4.80e-04 | 198 | 18 | 3 | 5334_DN | |
| Drug | C75; Up 200; 10uM; PC3; HT_HG-U133A | 4.80e-04 | 198 | 18 | 3 | 6428_UP | |
| Drug | Dextromethorphan hydrobromide monohydrate [6700-34-1]; Down 200; 10.8uM; PC3; HT_HG-U133A | 4.87e-04 | 199 | 18 | 3 | 6300_DN | |
| Drug | Nifenazone [2139-47-1]; Down 200; 13uM; HL60; HG-U133A | 4.87e-04 | 199 | 18 | 3 | 1439_DN | |
| Drug | 3-hydroxy-(D/L)-kynurenine; Down 200; 9.2uM; MCF7; HT_HG-U133A_EA | 4.87e-04 | 199 | 18 | 3 | 1109_DN | |
| Drug | Bumetanide [28395-03-1]; Down 200; 11uM; MCF7; HT_HG-U133A | 4.87e-04 | 199 | 18 | 3 | 5542_DN | |
| Drug | AH6809; Up 200; 1uM; PC3; HT_HG-U133A | 4.87e-04 | 199 | 18 | 3 | 7075_UP | |
| Disease | inositol measurement | 2.83e-05 | 14 | 17 | 2 | EFO_0010504 | |
| Disease | response to antidepressant | 1.33e-04 | 176 | 17 | 3 | GO_0036276 | |
| Disease | basophil percentage of leukocytes | 3.44e-04 | 243 | 17 | 3 | EFO_0007992 | |
| Disease | Neurodevelopmental Disorders | 1.30e-03 | 93 | 17 | 2 | C1535926 | |
| Disease | Weight Gain | 1.56e-03 | 102 | 17 | 2 | C0043094 | |
| Disease | Malignant neoplasm of liver | 2.98e-03 | 142 | 17 | 2 | C0345904 | |
| Disease | Liver neoplasms | 2.98e-03 | 142 | 17 | 2 | C0023903 | |
| Disease | unipolar depression, bipolar disorder | 3.59e-03 | 156 | 17 | 2 | EFO_0003761, MONDO_0004985 | |
| Disease | hair colour measurement | 4.93e-03 | 615 | 17 | 3 | EFO_0007822 | |
| Disease | body weight | 5.06e-03 | 1261 | 17 | 4 | EFO_0004338 | |
| Disease | lymphocyte count | 8.55e-03 | 1464 | 17 | 4 | EFO_0004587 | |
| Disease | non-melanoma skin carcinoma | 1.00e-02 | 265 | 17 | 2 | EFO_0009260 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| RNLRGQQRTRLLNKF | 416 | Q8WYA6 | |
| ALKQALRQQQKRRNG | 156 | Q9C0F0 | |
| RQRQQKQRQLLGRLQ | 941 | Q8N201 | |
| KQRRRAQKLHFLQRG | 831 | Q8TDD1 | |
| RNKRNRQNRSRGQGY | 646 | Q1KMD3 | |
| QKQLRGQIARRVYRQ | 796 | Q9HD67 | |
| FRQLGRQRRKQQGPK | 686 | Q8N9T8 | |
| RNLKLRQRNLKFQGA | 16 | Q9NVP1 | |
| QRTGKGNRRGRKRQQ | 66 | Q9BXL5 | |
| GRRKQRLRLSVFQQG | 151 | Q96BT3 | |
| GRAQRQRKGILKNRL | 3001 | Q9NYQ7 | |
| MGKLRRRYNIKGRQQ | 1 | Q8IY37 | |
| GQNLIKKVRNLRQRL | 1036 | Q96DN5 | |
| VRRNYGKRRGRNQQI | 491 | O75376 | |
| NNGNRRRRKLRKTVN | 156 | Q9UMS5 | |
| QGRQQRRGKQLKLFR | 941 | Q96JG9 | |
| GNNFVKKRRGRPRKQ | 1446 | Q9Y6X0 | |
| NRGSLLFQKRQRRVQ | 46 | Q8TDC0 |